Objective: We aimed to evaluate the quality and determinants of vitamin K antagonists (VKA) control among very elderly patients in geriatric settings.
Methods: A national cross-sectional survey was conducted among patients aged ≥80 years who were hospitalized in rehabilitation care or institutionalized in a nursing home and who were treated by VKA. Time in therapeutic range (TTR) was computed according to Rosendaal's method.
Results: A total of 2,633 patients were included. Mean [± standard deviation (SD)] age was 87.2 ± 4.4 years and 72.9 % were women. The main indication for VKA therapy was atrial fibrillation (AF; 71.4 %). Mean (±SD) TTR was 57.9 ± 40.4 %. After backward logistic regression, poorer VKA control (TTR <50 vs. ≥50 %) was associated with being hospitalized in rehabilitation care [odds ratio (OR)(rehab. vs. nursing home) = 1.41; 95 % CI 1.11-1.80], the indication for VKA treatment (OR(prosthetic heart valve vs. AF) = 4.76; 95 % CI 2.83-8.02), a recent VKA prescription (OR(<1 vs. >12 months) = 1.70; 95 % CI 1.08-2.67), the type of VKA (OR(fluindione vs. warfarin) = 1.22; 95 % CI 1.00-1.49), a history of international normalized ratio >4.5 (OR = 1.50; 95 % CI 1.21-1.84), a history of major bleeding (OR = 1.88; 95 % CI 1.00-3.53), antibiotic use (OR = 1.83; 95 % CI 1.24-2.70), and falls (OR(≥2 falls during the past year vs. <2) = 1.26; 95 % CI 1.01-1.56).
Conclusion: Overall, VKA control remains insufficient in very old patients. Poorer VKA control was associated with taking VKA for a prosthetic heart valve, a recent VKA prescription, the use of other VKAs than warfarin, a history of overcoagulation and major bleeding, antibiotic use, and falls.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40266-013-0127-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Warfarin and heparin monitoring in antiphospholipid syndrome.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Haematology, University College London Hospitals, London, United Kingdom.
Anticoagulation is central to the management of antiphospholipid syndrome (APS), an acquired thrombo-inflammatory disorder characterized by thrombosis (venous, arterial, or microvascular) or pregnancy morbidity, in association with persistent antiphospholipid antibodies (aPL; ie, 1 or more of lupus anticoagulant [LA], anticardiolipin, anti-beta-2- glycoprotein I, IgG, or IgM antibodies). The mainstay of anticoagulation in patients with thrombotic APS is warfarin or an alternative vitamin K antagonist (VKA) and, in certain situations, low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). Accurate assessment of anticoagulation intensity underpins optimal anticoagulant dosing for thrombus treatment or primary/secondary prevention.
View Article and Find Full Text PDFPoor clinical outcomes associated to multimorbidity, frailty and malnutrition in patients with atrial fibrillation.
J Nutr Health Aging
November 2024
Department of Hematology, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.
Article Synopsis
- A study was conducted on atrial fibrillation (AF) patients starting vitamin K antagonist (VKA) therapy to determine the effect of comorbidities, frailty, and malnutrition on clinical outcomes.
- The research found that a majority of patients had multiple health issues, and frailty significantly increased the risks for major bleeding and death, while malnutrition heightened the risk for strokes and overall mortality.
- These findings underline the importance of addressing these factors in AF patients to improve their health outcomes during VKA treatment.
Anticoagulation Usage and Thrombolytic Therapy in Subjects with Atrial Fibrillation Associated Ischaemic Stroke.
Int J Stroke
November 2024
Irish National Audit of Stroke, National Office of Clinical Audit. St Stephen's Green, Dublin 2. Ireland.
Background: Atrial Fibrillation (AF) causes up to 20% of ischaemic strokes and 30% in some populations such as those over 80 years. Previous research in our population showed that widespread adoption of Direct Oral Anticoagulant (DOAC) prophylaxis had not been associated with a reduction in AF associated stroke prevalence but there was a considerable rate of breakthrough stroke in patients receiving anticoagulation and anticoagulation rate may be affected by increasing use of DOACs.
Aims: We undertook a more detailed study using the Irish National Audit of Stroke (INAS) to determine the characteristics of anticoagulation practice in AF associated stroke, particularly breakthrough stroke, adherence to prescribing guidelines and effect on thrombolysis rate.
Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study.
PLoS One
November 2024
Pfizer LTD., Surrey, United Kingdom.
Background: This observational study compared effectiveness and safety of direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran) or vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) at high risk for gastrointestinal bleeding (GIB).
Methods: Anticoagulant-naïve adults with NVAF with ≥1 GIB risk factor, initiating anticoagulant treatment January 2016-December 2019, and covered by the French national health data system were eligible. Outcomes included major bleeding (MB) and stroke/systemic embolism (SE).
[Impact of therapeutic education on adherence in patients treated with anti-vitamins K].
Ann Cardiol Angeiol (Paris)
December 2024
Service de Médecine Interne CHU La Rabta Tunis, Faculté de Médecine de Tunis- Université Tunis-El Manar, Tunisie.
Introduction: Therapeutic education of the patient (TPE) treated with AVK has improved the safety and efficiency of this treatment by establishing a new doctor-patient relationship. The objective of our study was to assess the impact of a TPE program on adherence in patients treated with AVK.
Methods: We conducted a prospective interventional study between January and September 2020, including two groups of patients hospitalized for a first thromboembolic: a G1 group with conventional service support and a G2 group with an ETP program created during this work.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!